Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients with Adv Solid Tumors

Trial Identifier: MSC-1-101
Sponsor: AstraZeneca
NCTID:: NCT03490669
Start Date: May 2018
Primary Completion Date: September 2019
Study Completion Date: September 2019
Condition: Cancer - Other; Lung Cancer; Ovarian Cancer; Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Ontario Toronto, Ontario, Canada, M5G 1Z5
Spain Barcelona, Spain, 08035
United States, Arizona Scottsdale, Arizona, United States, 85258
United States, Michigan Grand Rapids, Michigan, United States, 49546
United States, New Jersey Middletown, New Jersey, United States, 07748
United States, New York New York, United States, 10065
United States, New York West Harrison, New York, United States, 10604